Novo Nordisk Partners for Weekly Weight Loss Pill Development

Danish pharmaceutical giant Novo Nordisk has entered into a significant deal with Chinese firm Hengrui to develop a new experimental weight loss pill designed for weekly administration. The agreement, potentially worth up to $2.6 billion, signals an escalation in the race among major pharmaceutical companies to create next-generation obesity and diabetes treatments.

Under the terms of the deal, Novo Nordisk will acquire exclusive global rights, excluding mainland China and certain other territories, to develop, manufacture, and market Hengrui's experimental drug, HRS-1596. The initial payment is $300 million, with up to an additional $2.3 billion contingent on development milestones, regulatory approvals, and commercial targets. Hengrui will also receive royalties on future sales.

The experimental drug targets both GLP-1 and GIP hormone receptors, a dual mechanism also found in other obesity drugs. However, HRS-1596 is being developed as an oral medication, unlike some existing treatments that require injections. The drug is currently prior to advanced clinical trials, though initial safety and characteristic studies have received approval in China.

This development follows the recent FDA approval of daily oral weight loss pills, including Novo Nordisk's own Wegovy (semaglutide) and Eli Lilly's Foundayo (orforglipron). Foundayo demonstrated significant weight loss in clinical trials, with participants losing an average of 12.4% of their body weight. The potential weekly oral pill aims to offer greater convenience than daily pills or injections.

The agreement highlights the intense competition in the lucrative weight loss drug market, with Western companies increasingly collaborating with Chinese biotech firms for novel drug candidates. Novo Nordisk plans to advance HRS-1596 into global clinical trials, but no timeline has been provided for potential approval in the US, Europe, or Israel.